Immune Pharmaceuticals (IMNPQ) Stock Price, News & Analysis

Company Overview

Immune Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of antibody-based therapies for immune-mediated and inflammatory diseases. The company’s research platform centers on novel monoclonal antibodies designed to modulate key pathways in chronic inflammatory conditions, including dermatological and gastrointestinal disorders.

Immune Pharmaceuticals’ lead product candidate is bertilimumab, a fully human monoclonal antibody targeting eotaxin-1, which has been studied in conditions such as bullous pemphigoid and ulcerative colitis. The company also holds rights to itolizumab, an anti-CD6 antibody licensed from Biocon, with potential applications in psoriasis, atopic dermatitis and other T-cell driven diseases. These programs are supported by preclinical and clinical data aimed at demonstrating safety and efficacy across a range of indications.

Headquartered in New York City, Immune Pharmaceuticals advances its pipeline through a combination of internal capabilities and strategic partnerships. The company collaborates with academic institutions and development partners across North America, Europe and Asia to conduct clinical trials and scale manufacturing. By leveraging targeted immunology expertise and global regulatory experience, Immune Pharmaceuticals seeks to address unmet needs in rare and chronic inflammatory disorders.

Key Stats

• Today's Range: $0.0010 to $0.0010
• 50-Day Range: N/A
• 52-Week Range: $0.0001 to $0.0070
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 6/22/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:IMNPQ
• CIK: 1208261
• Web: www.immunepharma.com
• Phone: (201) 464-2677
• Fax: 917-398-1915
• Employees: 7
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A